Stock comparison
IDEXX Laboratories
BeOne Medicines
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
ONC
BeOne Medicines
Market cap
$33.15B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | ONC | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 62D | IDXX |
| Benjamin Graham | 80A | 75D | IDXX |
| Philip Fisher | 75B | 84C | ONC |
| Peter Lynch | 71B | 75B | ONC |
| Joel Greenblatt | 83C | 49D | IDXX |
| Charlie Munger | 87A | 56D | IDXX |
| Terry Smith | 84A | 60D | IDXX |
Side-by-side metrics
| Metric | IDXX | ONC |
|---|---|---|
| Market cap | $44.12B | $33.15B |
| P/E (TTM) | 39.0x | 107.5x |
| EV/EBIT | 31.6x | 28.9x |
| ROIC (TTM) | 40.66% | 7.73% |
| Gross margin | 62.05% | 87.17% |
| Net margin | 24.63% | 8.93% |
| Revenue CAGR 5y | 7.56% | 45.99% |
| EPS CAGR 5y | 10.79% | 67.36% |
| Debt / Equity | 0.7x | 0.4x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- ROIC (TTM)40.66%vs 7.73%+81%
- Net margin24.63%vs 8.93%+64%
- P/E (TTM)39.0xvs 107.5x+64%
- Market cap$44.12Bvs $33.15B+25%
ONC leads on
- EPS CAGR 5y67.36%vs 10.79%+84%
- Revenue CAGR 5y45.99%vs 7.56%+84%
- Debt / Equity0.4xvs 0.7x+38%
- Gross margin87.17%vs 62.05%+29%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.